持续性肺动脉高压新生儿的神经发育结局
Neurodevelopmental outcome of newborns with persistent pulmonary hypertension.
作者信息
Rohana Jaafar, Boo Nem Yun, Chandran Viji, Sarvananthan Rajini
机构信息
Department of Paediatrics, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia.
出版信息
Malays J Med Sci. 2011 Oct;18(4):58-62.
BACKGROUND
Developmental disabilities have been reported in infants with persistent pulmonary hypertension of the newborn (PPHN) treated with inhaled nitric oxide (INO) or intravenous magnesium sulphate (MgSO(4)) and/or extracorporeal membrane oxygenation. This paper reports the rate of developmental disabilities at 2 years of age in a cohort of survivors of PPHN treated with INO, MgSO(4), or both during the neonatal period.
METHODS
Sixteen survivors of PPHN were prospectively followed up. These infants were treated with intravenous MgSO(4) and/or INO during the neonatal period. Neurodevelopmental assessment was carried out at 2 years of age using the Bayley Scales of Infant Development 2nd Edition by a developmental psychologist. Eleven (68.8%) infants completed the 2-year follow-up.
RESULTS
The median mental developmental index (MDI) and physical developmental index scores were 85 (interquartile range, IQR = 27) and 87 (IQR = 33), respectively. Two infants (18.2%) had developmental disability (MDI scores <70).
CONCLUSION
Survivors of PPHN are at risk of developmental disabilities. Early intervention programme and long-term follow-up should be integrated in the management of these infants.
背景
据报道，接受吸入一氧化氮（INO）或静脉注射硫酸镁（MgSO₄）和/或体外膜肺氧合治疗的新生儿持续性肺动脉高压（PPHN）婴儿存在发育障碍。本文报告了在新生儿期接受INO、MgSO₄或两者治疗的PPHN幸存者队列中2岁时的发育障碍发生率。
方法
对16名PPHN幸存者进行前瞻性随访。这些婴儿在新生儿期接受了静脉注射MgSO₄和/或INO治疗。在2岁时由一名发育心理学家使用贝利婴儿发育量表第二版进行神经发育评估。11名（68.8%）婴儿完成了2年的随访。
结果
平均智力发育指数（MDI）和身体发育指数得分分别为85（四分位间距，IQR = 27）和87（IQR = 33）。两名婴儿（18.2%）有发育障碍（MDI得分<70）。
结论
PPHN幸存者有发育障碍的风险。应将早期干预计划和长期随访纳入这些婴儿的管理中。
Zotero 插件